Halaman 1 dari 39 hasil
FIELD OF INVENTION
This invention relates to a formulation for reducing thymus atrophy, in particular, during the course of treatment of inflammation by dexamethasone. This invention also relates to a formulation for enhancing the anti-inflammatory effect of dexamethasone.
BACKGROUND OF
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to an anti-inflammatory or anti-sunburn cosmetic composition.
2. Description of the Prior Art
It is well known that the sunlight and/or lights by artificial light sources, in particular, ultraviolet rays have some
This application claims priority under 35 U.S.C. 371 to PCT/AU94/00424, filed Jul. 27, 1994.
TECHNICAL FIELD
The present invention relates to the treatment of inflammatory response in the macula of the eye.sup.1,2,3,4,5,6 by use of a depot injection into the vitreous humour of a suitable
Senile macular degeneration is one of the most common causes of reduction of vision after the age of 65. The condition is chronic with a progressive course. Even though some of the pathophysiological changes in the retina are known, the actual cause of the disease is not known, nor has there as yet
BRIEF SUMMARY OF THE INVENTION
This invention relates to novel compositions of matter useful as anti-inflammatory agents and as inhibitors of the progressive joint deterioration characteristic of arthritic disease. More particularly, it relates to therapeutic compositions containing certain
FIELD OF THE INVENTION
The invention is in the field of methods for medical treatment. It provides an improved method for repairing damaged cartilage and/or preventing cartilage degeneration and/or managing pain in tissue, in particular in a joint.
BACKGROUND OF THE INVENTION
During our life moving,
BRIEF SUMMARY OF THE INVENTION
This invention relates to new organic compounds and, more particularly, is concerned with novel substituted cis-2-benzoyl-3-hydroxy-2-alkenonitriles and the pharmacologically acceptable cationic salts thereof which may be represented by the following structural
FIELD OF THE INVENTION
The invention pertains to the field of Noble Gases, more particularly the invention pertains to augmentation of anti-inflammatory, immune modulatory, and regenerative activities of known agents using the inert gas Xenon and other compositions containing Noble Gases.
BACKGROUND
TECHNICAL FIELD
The invention relates to a preparation for external use containing a nonsteroidal antiinflammatory and analgesic drug and, in particular, the preparation for external use blended with a UV absorption agent to inhibit effects of light on the nonsteroidal antiinflammatory and analgesic
BACKGROUND OF THE INVENTION
Eye disease is a significant cause of morbidity in the U.S. and throughout the world. While therapies have improved over time for many eye diseases, there remain many others for which therapy is of limited or no benefit.
Diseases of the retina, including age-related
FIELD OF THE INVENTION
This invention generally relates to methods of photodynamic therapy and compositions for treating ocular conditions. More particularly, this invention relates to the use of photodynamic therapy used in conjunction with one or more additional therapies, more particularly
FIELD OF THE INVENTION
The present invention relates to compositions comprising sulfated polysaccharides and uses thereof.
BACKGROUND OF THE INVENTION
According to the world health organization (WHO), reproductive and sexual ill-health accounts for 20% of the global sickness in women and therefore
BACKGROUND OF THE INVENTION
The present invention relates to cyclic sulfone derivatives which are inhibitors a matrix metalloproteinases or the production of tumor necrosis factor (TNF) and as such are useful in the treatment of a condition selected from the group consisting of arthritis, cancer,
BACKGROUND OF THE INVENTION
The present invention relates to arylsulfonylamino hydroxamic acid derivatives which are inhibitors of matrix metalloproteinases or the production of tumor necrosis factor (TNF) and as such are useful in the treatment of a condition selected from the group consisting of
The present invention relates to arylsulfonylamino hydroxamic acid derivatives which are inhibitors of matrix metalloproteinases or the production of tumor necrosis factor (TNF) and as such are useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue